Csr Pharma
-
Upload
ravinayudugee -
Category
Documents
-
view
216 -
download
0
Transcript of Csr Pharma
-
8/6/2019 Csr Pharma
1/11
Corporate Social Responsibility in the
pharmaceutical industry
The Novo Nordisk Way..
Dialogue and ActionMadrid 24 November 2006
Lars Rebien Srensen
President and CEO
Novo Nordisk A/S
-
8/6/2019 Csr Pharma
2/11
Page 2Dialogue and Action
The business of business is business!
But when the time horizon is long enough
social and environmental challengesbecome crucial for companies to retaintheir license to operate
Lars Rebien Srensen,November, 2006
-
8/6/2019 Csr Pharma
3/11
Page 3Dialogue and Action
Pressure on the pharmaceutical industry
Research &Development
Sales &Marketing
ProductionStakeholderneeds
Stakeholdersuccess
Innovation andbusiness model
Healthcarecost containment
All-time lowstakeholder trust
-
8/6/2019 Csr Pharma
4/11
Page 4Dialogue and Action
Challenges for the industry
Pharmaindustry
Increasing focus on
risk management
Increasing focus onproduct innovation and
solving real medical needs
Increasing focus on
business practices
Increasing focus ongood citizenship
Increasing need forjoint solutions and
a broader business design
Industry challenges:Innovation, cost and trust
-
8/6/2019 Csr Pharma
5/11
Page 5Dialogue and Action
The Triple Bottom Line- integrating ethics and business
Business ethics
Bio ethicsHuman ethics
Economically viableCorporate profitability and growth
Socio- and health economics
Diabetes care
Biopharmaceuticals
Socially responsibleEmployees, patients,
communities
Environmentally soundExternal environment,experimental animals
-
8/6/2019 Csr Pharma
6/11
Page 6Dialogue and Action
Identifying present and future issues
Level oflearning
Responsiblelobbying
Full business integration
Strategy revisitedLevel ofintegration
Issue identification
Review and strategy
Stakeholder dialogueIndicators, data and targets
Embedding in the organisation
Health and safetyBioethics
Sustainable supply chain
Environmental management
Human rightsAccess to health
Diversity
Globalisation
Business ethicsClimate change
Socio-economics
Healthy lifestyles
Trend spotting,stakeholder engagement
-
8/6/2019 Csr Pharma
7/11
Page 7Dialogue and Action
Novo Nordisks business approach
CORPORATEGOVERNANCE
CLIMATECHANGE
GLOBALSOCIETY LEVEL COMBATING
CHRONIC DISEASES
HUMANRIGHTS
BUSINESSETHICS
ACCOUNTABLEPARTNERSHIPS
DIVERSITY
RESPONSIBLELOBBYING
ACCESS TOHEALTH
PUBLICHEALTH STRATEGY
INFRA-STRUCTURE
NATIONALCHANGING DIABETES
PROGRAMMES
ADDITIONALFUNDING
SOCIO-ECONOMICS
PRICINGSCHEMES
ACCESSTO CARE
EDUCATION
AWARENESSPRODUCTQUALITY
PRODUCTSAFETY
DAWN CUSTOMERINNOVATION
CUSTOMERSATISFACTION
OPTIMALCONTROL
RESEARCH &DEVELOPMENT
IPR, QUALITY,REGULATORY
PRODUCTION MARKETING SALES,DISTRIBUTION
NATIONALMARKET LEVEL
PATIENTLEVEL
-
8/6/2019 Csr Pharma
8/11
Page 8Dialogue and Action
Is climate change a real problem?
The precautionaryprinciple assumes thatthere is a risk, when wecannot prove if the risk is
real
-
8/6/2019 Csr Pharma
9/11
Page 9Dialogue and Action
Without cLEAN
Without CO2 strategy
A strategy to address climate change
350,000 t
210,000 t
2004 CO2 line
>158,000 t
192,000 t
~
280,000 t
630,000 tCO2 emissions
Target 10%reduction
by 2014
2004 2006 2008 2010 20142012
With cLEAN
Without CO2 strategy
With cLEAN
With CO2 strategy
-
8/6/2019 Csr Pharma
10/11
Page 10Dialogue and Action
Strategy to provide improved access tohealth for people with diabetes
WHO priorities
Development of nationalhealthcare strategies
Development ofhealthcare capacity
Best possible pricing
Additional funding
Novo Nordisk's response
National DiabetesProgramme & DAWN
National DiabetesProgramme
Best possible pricingscheme in LDCs
World DiabetesFoundation
-
8/6/2019 Csr Pharma
11/11
Page 11Dialogue and Action
Conclusions why an ethical approachmakes good business sense
License to operate and innovate
Proactive risk management
New business opportunities
Innovation
Employee engagement
Stakeholder trust and market credibility